Online citations, reference lists, and bibliographies.
← Back to Search

A Comparison Of The Spread Of Three Formulations Of Botulinum Neurotoxin A As Determined By Effects On Muscle Function

S. Dodd, B.A. Rowell, I.S. Vrabas, R.J. Arrowsmith, P.J. Weatherill
Published 1998 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
The purpose of these experiments was to compare the spread of three formulations of botulinum neurotoxin A. A gelatin/phosphate buffer (C), DysportR (D {0.5 U}, BotoxR (B {0.167 U}), or a purified preparation of botulinum neurotoxin A [Bont A] (BA {0.5 U}) was injected into the tibialis anterior of male, Wistar rats. After 4 days, the adjacent extensor digitorum longus muscle was isolated in situ and the nerve was maximally stimulated to determine contractile properties and the rate of fatigue. There were no differences in body or muscle weights between any of the groups after 4 days of treatment. Maximal twitch and tetanic tensions were decreased ≈ 25% (p < 0.05) in all treatment groups compared to C. In addition, rate of tension development was significantly less in all treatment groups compared to C but one‐half relaxation time and time to peak tension were not different between any groups. Fatigue of the muscle was significantly faster in all groups compared to C but there was no difference between treatment groups. These data indicated that botulinum toxin A injected intramuscularly was likely to spread to adjacent muscles but that the spread was not different between the three formulations tested. The effect of the spread ranged from a slight to a severe reduction in maximal tension but this did not occur in all animals studied.
This paper references
Three-dimensional tissue deformation in subcutaneous tissues overlying bony prominences may help to explain external load transfer to the interstitium.
K. Dodd (1991)
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
S. Kraft (1988)
Responsiveness of idiopathic spasmodic torticollis to botulinum a toxin injection. a critical evaluation of five cases
Sandro Maurri (1990)
Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles.
L. Duchen (1970)
Distant effects of local injection of botulinum toxin
D. Lange (1987)
Ca2+ influx insensitive to organic Ca2+ entry blockers contributes to noradrenaline-induced contractions of the isolated guinea pig aorta.
M. A. Gouw (1990)
Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia
A. Buchman (1994)
Dose standardisation of botulinum toxin
A. Pickett (1994)
Dose standardisation of botulinum toxin.
M. Marion (1995)
The determinants of skeletal muscle force and power: their adaptability with changes in activity pattern.
R. Fitts (1991)
Botulinum toxin injections for cervical dystonia
J. Jankovic (1990)
Muscle filament structure and muscle contraction.
J. Squire (1975)
The effect of botulinum toxin type a injection on compound muscle action potential in an in vivo rat model
J. Cichon (1995)
Potency equivalence of botulinum toxin preparations.
P. Hambleton (1994)
Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization
J. O. Dolly (1984)
Botulinum toxin-induced myopathy in the rat.
S. M. Hassan (1995)
Botulinum toxin for blepharospasm: single-fiber EMG studies
D. Sanders (1986)

This paper is referenced by
Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis
H. E. El Kahky (2013)
Botulinum Toxin in Aesthetic Medicine
B. Rzany (2007)
Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
Debraj Shome (2019)
Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications
A. Pickett (2008)
Clinical Applications of Botulinum Neurotoxin
K. Foster (2014)
Botulinum toxin for the treatment of cervical dystonia
J. Jankovic (2001)
Advanced Indications and Techniques
M. D. Maio (2007)
A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport®) in the Treatment of Spastic Equinovarus Deformity after Stroke
S. Pittock (2003)
Botulinum toxin B increases mouth opening in patients with spastic trismus
U. Fietzek (2009)
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
J. Park (2011)
Botulinum toxin pretreatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle.
S. Christiansen (2008)
The botulinum toxin as a therapeutic agent: molecular and pharmacological insights
R. Kukreja (2015)
Detection of Botulinum Toxin Muscle Effect in Humans Using Magnetic Resonance Imaging: A Qualitative Case Series
M. O'dell (2017)
Botulinum neurotoxin — from laboratory to bedside
K. Foster (2009)
The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations.
Andy M Pickett (2008)
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
J. Jimenez-Shahed (2012)
Diffusion, spread, and migration of botulinum toxin
Juan Ramirez-Castaneda (2013)
Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg
L. Carli (2009)
Consensus panel's assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics.
Z. P. Lorenc (2013)
Análisis de impacto presupuestario del uso de la toxina botulínica tipo A (TBA) en el Sistema Nacional de Salud en España
Gloria Tapias (2013)
Chapter 32 – Properties of Pharmaceutical Products of Botulinum Neurotoxins
H. Bigalke (2009)
Botulinum Toxin in Facial Palsy: An Effective Treatment for Contralateral Hyperkinesis
M. de Maio (2007)
Botulinum toxin type A products are not interchangeable: a review of the evidence
M. Brin (2014)
Influence of injection of Chinese botulinum toxin type A on the histomorphology and myosin heavy chain composition of rat gastrocnemius muscles
B. Hong (2013)
Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle.
S. Dodd (2005)
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
J. Frevert (2010)
Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations
M. Alimohammadi (2017)
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology
A. Pickett (2014)
IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.
Z. P. Lorenc (2013)
Semantic Scholar Logo Some data provided by SemanticScholar